DN
Therapeutic Areas
MiNK Therapeutics Pipeline
| Drug | Indication | Phase |
|---|---|---|
| agenT-797 | Solid Tumors | Phase 1/2 |
| Engineered iNKT Cell Programs (e.g., CAR-iNKT) | Precision Oncology Targets | Preclinical |
Leadership Team at MiNK Therapeutics
JB
Jennifer Buell, Ph.D.
Chief Executive Officer
SC
Sandra Craig
Executive Director of Manufacturing
RS
Robert Stein, M.D., Ph.D.
Scientific Advisor
MH
Manuel Hidalgo, M.D., Ph.D.
Scientific Advisor
ME
Mark Exley, Ph.D.
Scientific Advisor
JG
Jenny Gumperz, Ph.D.
Scientific Advisor